BioSpace News Archive

Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, that Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has exercised an option through the parties’ drug discovery collaboration to identify new small molecule-ba

Lungpacer Medical announced today that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the Company’s novel Diaphragmatic Pacing Therapy System (DPTS) for immediate use in patients on invasive mechanical ventilators at high risk of weaning failure, including COVID-19 patients.

- Now available in a third vial size (3-mL - 900-IU), HyperRAB, the only high-potency formulation of rabies immunoglobulin, gives healthcare professionals more convenient dosing options, reduces storage space and minimizes unnecessary waste - HyperRAB is presently the number one prescribed rabies immunoglobulin in the U.S., with over 1 billion international units administered to more than 1 million patients over 45 years - Grifols continues to expand its leadership in disease

VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that the Company’s annual financial statements and management discussion and analysis for the year ended December 31, 2019 are now available to download on the Company’s website at www.vaxil-bio.com/ and on Sedar at www.sedar.com . The following is a summary

SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced it has received approval of their Investigational Device Exemption (IDE) supplement from the U.S. Food and Drug Administration (FDA) to initiate a feasibility, compassionate use study

Positive growth and strong cash flow First quarter Net sales amounted to 277.3 MSEK (248.0), an increase by 11.8 percent compared to the corresponding quarter last year. At comparable exchange rates sales increased by 7.1 percent. Operating profit increased by 23.2 percent to 61.4 MSEK (49.8). Result after tax amo

Proposed Phase 2 Study to Take Place in New York City Under U.S. FDA’s Coronavirus Treatment Acceleration Program (CTAP)

The molecule has the potential to be developed into a drug that can treat Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients

In their brand new report " COVID-19 Diagnostics ", global market research firm IDTechEx benchmarked more than 100 commercial devices across various technologies, providing a deep insight into the technology trends and biotech innovations surrounding the COVID-19 global response. For more information on this report, please visit www.IDTech

Includes Details About Company’s Community Involvement, Ethical Marketing & Drug Safety